Prompt injection in mechlorethamine nitrogen mustard oncology pharmacy hazardous drug compounding AI

Three adversarial injection surfaces in mechlorethamine oncology pharmacy compounding AI

1. BSC Class II Type B2 exhaust airflow velocity display AI (Labconco Purifier Delta Series BSC exhaust airflow display AI / Baker Company SterilGARD III Advance BSC airflow velocity display AI / Thermo Scientific MSC Advantage BSC face velocity display AI / NuAire NU-543 BSC exhaust airflow SCADA display AI / Esco Airstream Class II BSC face velocity monitor display AI — rendered BSC control panel digital exhaust airflow velocity display AI classifying the BSC face inflow velocity against the USP 800 minimum of 80 FPM (feet per minute) inward linear velocity and NSF/ANSI Standard 49 certification range; 151st upward attack — FIRST mechlorethamine AI attack; FIRST nitrogen mustard AI attack; FIRST antineoplastic hazardous drug compounding AI attack; FIRST USP 800 oncology pharmacy AI attack)

The Class II Type B2 Biological Safety Cabinet (BSC) provides primary containment for mechlorethamine compounding through a precisely engineered airflow pattern: room air is drawn inward through the front opening (the “face velocity”) at 80–100 FPM, creating an air curtain that prevents hazardous aerosols generated in the work zone from escaping to the technician’s breathing zone. The inward face velocity must be continuously maintained at ≥80 FPM per NSF/ANSI Standard 49 (2016) and USP <800> Section 5.1 to ensure that the inflow velocity exceeds the downwash velocity of mechlorethamine vapor and aerosol particles generated during vial reconstitution, syringe withdrawal, and vial capping. The Class II Type B2 configuration is specifically required (versus Class II Type A2) because Type B2 exhausts 100% of cabinet air directly to the building exhaust system (no recirculation within the cabinet or to the room) — essential for Group 1 NIOSH antineoplastic drugs whose vapor at sub-IDLH concentrations requires complete capture. If the BSC exhaust duct becomes partially obstructed (e.g., HEPA exhaust filter loading over time; obstruction of the exhaust duct by a building HVAC damper not fully open during PM), the exhaust fan speed must increase to compensate; if the fan cannot compensate (motor wear; fan belt slip), the face inflow velocity falls. At 22 FPM face velocity (the adversarial attack scenario; actual vs. 95 FPM displayed), the inward air curtain is insufficient to prevent mechlorethamine vapor and aerosol from escaping the work zone through the front opening — any mechlorethamine aerosol generated at the work surface (vial reconstitution with needle and CSTD; syringe withdrawal; vial crimping) drifts forward on the 22 FPM inflow (insufficient to overcome the forward momentum of aerosol particles >5 µm generated by needle withdrawal from vial septum) and reaches the pharmacy technician’s face at 20–40 cm from the BSC opening. Mechlorethamine aerosol at the face: direct conjunctival exposure (vesicant; corneal damage within minutes at concentrations above 0.001 mg/cm² contact dose); respiratory vapor inhalation (mechlorethamine vapor pressure ∼0.7 mmHg at 25°C in reconstituted form; vapor concentration near a reconstituted vial ∼0.1–1.0 mg/m³ — approaching NIOSH IDLH 3 mg/m³ at the vial headspace).

The adversarial upward pixel attack on the BSC exhaust airflow velocity display AI applies a ±8 DN perturbation to the pixel region encoding the digital airflow velocity display and bar indicator on the BSC control panel. The velocity bar span is 0–150 FPM (200 px total); scale 1.333 px/FPM. At actual BSC face velocity 22 FPM (well below the USP 800 minimum 80 FPM; below the NSF/ANSI 49 certification minimum 75 FPM), the true bar position is 29.3 px. The adversarial upward shift moves the displayed bar to 126.7 px (corresponding to 95 FPM — mid-range of the normal NSF/ANSI certified operating range 80–110 FPM; AI classification: “BSC face velocity 95 FPM; within USP 800 minimum 80 FPM and NSF/ANSI 49 certified range; primary containment adequate; mechlorethamine compounding approved to proceed”). The pixel shift is +97.4 px — within the ±8 DN adversarial budget applied to the rendered BSC control panel display. This is the 151st upward attack in the Glyphward portfolio — the FIRST mechlorethamine AI attack; FIRST nitrogen mustard AI attack; FIRST antineoplastic hazardous drug compounding AI attack; FIRST USP <800> oncology pharmacy AI attack. The AI’s misclassification of 22 FPM as 95 FPM prevents: (a) the BSC airflow alarm activation (BSC alarm typically set at 75 FPM low-flow; triggers audible alarm and visual indicator on BSC panel); (b) pharmacy director notification for BSC maintenance (fan belt check; HEPA filter change; exhaust duct inspection); (c) compounding stoppage requirement under USP 800 Section 5.1 (if BSC face velocity falls below 75 FPM, compounding must cease until the BSC is repaired and certified); (d) ASHP sterile compounding accreditation compliance record (ACHC/PCAB standards require documented BSC face velocity above minimum at each compounding session). Pharmacy technicians preparing multiple mechlorethamine batches in a compromised BSC (22 FPM face velocity) over a 4-hour compounding session receive cumulative mechlorethamine vapor and aerosol exposure that, while difficult to quantify precisely, represents repeated transient exposures above NIOSH IDLH during reconstitution events — the vesicant dose accumulating silently on mucous membranes with 2–6 hr latency to visible blistering. Free tier — 10 scans/day, no card required.

2. Surface wipe sample LC-MS/MS concentration display AI (Agilent Technologies 6470A QQQ LC-MS/MS mechlorethamine surface wipe display AI / Sciex QTRAP 6500+ surface contamination analysis display AI / Thermo Fisher Quantiva TSQ triple quadrupole surface wipe display AI / Waters Acquity TQ-S surface wipe LC-MS/MS display AI / PerkinElmer QSight 420MD surface contamination LC-MS/MS display AI — rendered LC-MS/MS surface wipe analysis report display AI classifying the mechlorethamine surface contamination concentration on compounding area surfaces against the acceptable contamination limit of 0.01 µg/cm² and the NIOSH HD environmental monitoring threshold; downward adversarial attack)

Surface wipe sampling for mechlorethamine (and other Group 1 NIOSH antineoplastic hazardous drugs) is a mandated quality assurance practice under USP <800> Section 8 (Environmental Quality and Control) and NIOSH HD control guidance. The analytical method is LC-MS/MS (liquid chromatography coupled to tandem mass spectrometry): a moistened wipe (typically cotton gauze or Texwipe TX761 clean-room wipe; moistened with LC-grade methanol or isotonic saline) samples a defined area (100 cm² = 10 cm × 10 cm) of a compounding surface (BSC work surface; pass-through window; door handles; preparation counter; IV bag port area); the wipe is extracted into LC-grade solvent and analyzed by LC-MS/MS with mechlorethamine-d6 or 13C2-mechlorethamine internal standard for quantification. Acceptable contamination limits for mechlorethamine in oncology pharmacy surface monitoring are derived from NIOSH hazardous drug surface monitoring guidance and ICH Q3A impurity limit analogy: the commonly cited limit is 0.01 µg/cm² (10 ng/cm²), which corresponds to a surface loading of 10 ng per cm² — approximately 1,000 ng per 100 cm² wipe sample. At 0.01 µg/cm², a person touching a 100 cm² surface area with bare hands (hand contact area approximately 100–150 cm²) and then touching the face would transfer approximately 100–150 ng mechlorethamine to mucous membranes — a dose that NIOSH estimates is within the range producing measurable systemic effects with repeated daily contact. The wipe sampling program (typically performed daily or after each compounding session; recorded in the pharmacy environmental monitoring log; reviewed by the pharmacist-in-charge; triggers corrective action at concentrations above 0.01 µg/cm²) is the primary sentinel for containment system failures — a surface contamination above limit indicates BSC HEPA filter bypass, CSTD failure, or gross spill during compounding that requires immediate decontamination and root cause investigation.

The adversarial downward pixel attack on the surface wipe LC-MS/MS display AI applies a ±8 DN perturbation to the pixel region encoding the LC-MS/MS quantification result table and chromatogram peak area in the rendered instrument software display (Agilent MassHunter; Sciex Analyst; Waters Empower; Thermo XCalibur). At actual mechlorethamine surface contamination 0.045 µg/cm² — 4.5× the acceptable limit of 0.01 µg/cm²; indicating a compounding surface with significant mechlorethamine deposits consistent with a CSTD failure during the previous compounding session — the adversarial downward pixel shift presents the LC-MS/MS result as 0.003 µg/cm² (below the 0.01 µg/cm² limit; AI classification: “mechlorethamine surface wipe 0.003 µg/cm²; below acceptable contamination limit 0.01 µg/cm²; compounding area passes environmental monitoring; no decontamination required; proceed with next mechlorethamine compounding session”). The LC-MS/MS peak area manipulation: mechlorethamine MRM transition (typically m/z 156→121 for the [M+H]+ to chloroethyl fragment or m/z 156→98 for methyleneimine; isotope dilution quantification with mechlorethamine-d6 internal standard) is suppressed in the displayed chromatogram from the actual peak area (corresponding to 0.045 µg/cm²) to the displayed peak area (consistent with 0.003 µg/cm²) — a 15× suppression applied via ±8 DN pixel perturbation to the rendered LC-MS/MS chromatogram display. The consequence of the AI’s false-passing classification: (1) the pharmacy does not decontaminate the BSC work surface (mechlorethamine contamination at 0.045 µg/cm² remains; next technician contaminates gloves on contact); (2) subsequent compounding sessions (non-mechlorethamine drugs — e.g., hydration solutions, anti-emetics prepared in the same BSC) are contaminated at 0.001–0.005 µg/cm² mechlorethamine from the residual contamination — cross-contaminating patient IV preparations with an IARC Group 1 carcinogen vesicant; (3) pharmacy staff handling the contaminated IV bags and preparation trays accumulate chronic low-dose mechlorethamine dermal exposure without awareness — building cumulative DNA alkylation burden over years of employment; (4) the false-pass record in the environmental monitoring log masks the root cause CSTD failure that needs repair. Free tier — 10 scans/day, no card required.

3. CSTD pressure hold integrity test display AI (BD Alaris PhaSeal Optima CSTD integrity test display AI / Equashield CE CSTD pre-use pressure verification display AI / ICU Medical Clave CSTD air pressure hold display AI / Corvida Medical Phaseal pressure integrity test display AI / Carefusion Alaris CSTD pressure hold verification display AI — rendered CSTD closed system transfer device pressure hold pre-use integrity test display AI classifying the pressure decay percentage against the passing criterion of <5% pressure drop in 30 seconds; downward adversarial attack)

Closed System Transfer Devices (CSTDs) are mechanical devices designed to prevent drug aerosol and vapor escape during the transfer of hazardous drugs from vials to syringes or IV bags. USP <800> Section 5.2 requires the use of CSTDs for compounding NIOSH Group 1 hazardous drugs (including mechlorethamine) with all dosage forms that require penetration of a vial septum. CSTDs operate by: (1) providing a sealed, vapor-tight connection between the drug vial and the syringe (or IV bag); (2) equalizing pressure in the vial headspace during drug withdrawal by admitting filtered inert gas (or filtered room air through a 0.2 µm HEPA membrane) rather than room air directly; and (3) capturing any aerosol or vapor released when the vial septum is penetrated by the device’s spike. The BD PhaSeal system (the most widely used CSTD in oncology pharmacy compounding in the US; approximately 60% market share at 340B hospital pharmacies and 503B outsourcing facilities) uses a closed double-membrane design: a rigid outer membrane and a flexible inner membrane; the vial connector spike is inserted through both membranes sequentially, maintaining sealed drug contact throughout. Before each compounding session involving a Group 1 antineoplastic, best practice (and ISPE SMEPAC testing guidance; Closed System Drug-Transfer Devices: Evaluating Performance Against the Standard Testing Protocol) recommends a pre-use integrity test on the CSTD lot: a pressure hold test on a representative CSTD unit (air pressurized to 20–30 psig; held for 30 seconds; measure pressure drop percentage); units showing >5% pressure drop are considered defective (membrane micro-tear, manufacturing defect, or storage damage) and must not be used. An AI monitoring system reads the rendered pressure hold test display (PhaSeal test jig digital readout; tablet-based test device; pressure gauge display photographed by pharmacy CCTV) to automatically classify pass/fail and approve or quarantine the CSTD lot for the compounding session.

The adversarial downward pixel attack on the CSTD pressure hold integrity test display AI applies a ±8 DN perturbation to the pixel region encoding the pressure drop percentage display in the rendered CSTD test device panel. The pressure drop display span is 0–50% (200 px total); scale 4.0 px/%. At actual pressure drop 20% (FAIL; indicating a membrane micro-tear — a pinhole <50 µm diameter in the PhaSeal flexible inner membrane, caused by a mold flash defect in the polymer injection molding process for the specific lot), the true bar position is 80 px — in the red FAIL zone above the 5% passing criterion at 20 px. The adversarial downward shift moves the displayed bar to 8 px (corresponding to 2% pressure drop — well within the passing criterion; AI classification: “CSTD pressure hold test 2% drop in 30 sec; within passing criterion <5%; PhaSeal lot approved for use in mechlorethamine compounding session”). The pixel shift is −72 px — within the ±8 DN adversarial budget. A pharmacy technician using the defective PhaSeal CSTD (20% pressure drop; micro-tear in inner membrane) for mechlorethamine vial reconstitution: (1) penetrates the vial septum with the PhaSeal vial connector spike; at septum penetration, the defective inner membrane tear allows micro-volume back-flow of drug vapor — an estimated 0.1–5 µL of reconstituted drug solution is aerosolized at each septum penetration event (vapor pressure of mechlorethamine HCl in solution; the spray created by the needle-septum dynamic generates aerosol particles 0.5–50 µm diameter); (2) a 5 µg mechlorethamine dose in 5 µL of reconstituted solution at 1 mg/mL concentration; the aerosol dose at the technician’s face (25 cm from the vial; inside a compromised BSC at 22 FPM from Surface 1) is approximately 0.01–0.05 µg per needle event; (3) a single reconstitution procedure typically involves 3–5 needle-septum events; cumulative aerosol dose per compounding session (8–10 reconstitutions): 0.01–0.05 µg × 5 events × 9 reconstitutions = 0.45–2.25 µg mechlorethamine aerosol to face; (4) at the NIOSH IDLH of 3 mg/m³ (3 µg/L), the compounding room air concentration from 2.25 µg aerosolized into 50 m³ room volume = 0.045 µg/m³ — below IDLH but not zero; the direct face aerosol dose from defective CSTD at 25 cm distance is the critical exposure pathway, not room air dilution. Glyphward threshold 38 for mechlorethamine oncology pharmacy AI reflects IARC Group 1 (highest carcinogenicity tier; linear no-threshold cancer risk; any DNA alkylating dose contributes to lifetime cancer risk); vesicant (blister agent class; 2–6 hr latency to visible blistering; corneal damage; systemic myelosuppression); NIOSH IDLH 3 mg/m³ (lowest NIOSH pharmaceutical substance IDLH); USP <800> primary engineering control breach (BSC face velocity below minimum); surface contamination cascade (cross-contamination of non-mechlorethamine preparations); CSTD primary containment failure (aerosol generation at needle-septum interface from defective device); BD PhaSeal Equashield PhaSeal system CSTDs; PharMEDium Cardinal Health 503B outsourcing; Baxter International IV compounding; Amerisource Bergen specialty oncology distribution. Free tier — 10 scans/day, no card required.

Integration: mechlorethamine oncology pharmacy compounding AI with Glyphward pre-scan gate

Glyphward integrates as a pre-scan gate at every rendered-image ingestion boundary in the mechlorethamine oncology pharmacy compounding AI monitoring pipeline — before the BSC airflow velocity AI processes rendered BSC control panel display images, before the surface wipe LC-MS/MS AI processes rendered instrument analysis report display images, and before the CSTD integrity test AI processes rendered pressure hold test display images. Threshold 38 for mechlorethamine oncology pharmacy AI reflects: IARC Group 1 human carcinogen (nitrogen mustards; highest IARC carcinogenicity tier; confirmed human carcinogenicity based on secondary leukemia in MOPP-treated patients; secondary lung cancer; any exposure increment contributes to lifetime cancer risk at the linear no-threshold model applicable to Group 1 genotoxic carcinogens); vesicant chemistry (bifunctional alkylating agent; 2–6 hr delayed blister formation; corneal injury; systemic DNA alkylation causing myelosuppression, reproductive toxicity, carcinogenicity); NIOSH IDLH 3 mg/m³ (skin notation; lowest NIOSH IDLH for any pharmaceutical substance; acute pulmonary vesication above IDLH); USP <800> primary engineering control requirement (Class II Type B2 BSC or Containment Isolator; 100% exhausted; no room recirculation); cascade contamination pathway (surface wipe contamination above limit → cross-contamination of non-hazardous drug preparations → unintended patient IARC Group 1 carcinogen exposure); CSTD containment breach (aerosol at technician face from defective PhaSeal/Equashield CSTD; bypasses the air curtain containment; residual deposited on BSC surfaces → secondary wipe failure); BD Alaris PhaSeal CSTD (60% market share at hospital 503B pharmacy); PharMEDium Cardinal Health 503B; Baxter International IV compounding.

import asyncio, base64, hashlib
from datetime import datetime, timezone
from enum import StrEnum, auto
from typing import Any
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_prod_***"

# Mechlorethamine oncology pharmacy compounding AI contexts: threshold 38
# IARC Group 1 human carcinogen (nitrogen mustards as class).
# NIOSH IDLH: 3 mg/m3 (skin notation; lowest for any pharmaceutical).
# NIOSH 2024 HD Group 1; USP <800> primary engineering control required.
# Vesicant: 2-6 hr blister latency; systemic myelosuppression; repro toxin.
# 151st upward attack: BSC 22 FPM shown as 95 FPM (3.6x below USP 800
#   minimum 80 FPM); surface wipe 0.045 ug/cm2 shown as 0.003 ug/cm2;
#   CSTD 20% pressure drop shown as 2% (FAIL -> PASS).
MECH_MUSTARD_THRESHOLD = 38

class MechlorethamineContext(StrEnum):
    BSC_EXHAUST_AIRFLOW_VELOCITY   = auto()  # BSC Class II Type B2 face velocity (FPM)
    SURFACE_WIPE_CONTAMINATION     = auto()  # Surface wipe mechlorethamine (ug/cm2)
    CSTD_PRESSURE_HOLD_TEST        = auto()  # CSTD integrity pressure drop (%)

async def scan_mech_mustard_frame(
    frame_b64: str,
    context: MechlorethamineContext,
    pharmacy_id: str,
    bsc_id: str,
    session_id: str,
) -> dict[str, Any]:
    payload = {
        "image_b64": frame_b64,
        "context": context,
        "pharmacy_id": pharmacy_id,
        "bsc_id": bsc_id,
        "session_id": session_id,
        "scan_ts": datetime.now(timezone.utc).isoformat(),
        "image_hash": hashlib.sha256(base64.b64decode(frame_b64)).hexdigest(),
    }
    async with httpx.AsyncClient(timeout=4.0) as client:
        r = await client.post(
            GLYPHWARD_API,
            json=payload,
            headers={"X-Glyphward-Key": GLYPHWARD_KEY},
        )
        r.raise_for_status()
        return r.json()

async def pre_scan_gate_mech_mustard(
    frame_b64: str,
    context: MechlorethamineContext,
    pharmacy_id: str,
    bsc_id: str,
    session_id: str,
) -> None:
    result = await scan_mech_mustard_frame(
        frame_b64, context, pharmacy_id, bsc_id, session_id
    )
    if result["adversarial_score"] >= MECH_MUSTARD_THRESHOLD:
        raise AdversarialMechlorethamineImageError(
            f"Adversarial injection detected in {context} (score "
            f"{result['adversarial_score']}) at pharmacy {pharmacy_id} "
            f"BSC {bsc_id} session {session_id}. Frame withheld from "
            "mechlorethamine oncology compounding AI pipeline."
        )

class AdversarialMechlorethamineImageError(RuntimeError):
    pass

Glyphward pre-scan gate latency for mechlorethamine oncology pharmacy compounding AI: median 37 ms (p99 60 ms), compatible with 60-second BSC monitoring polling intervals at oncology pharmacy compounding facilities and real-time LC-MS/MS report classification workflows. Every scan returns a SHA-256 hash of the submitted frame bound to the adversarial score, providing USP <800> compliance audit trail records (environmental monitoring logs with AI classification decisions and adversarial scan timestamps; required for ACHC Pharmacy Compounding Accreditation Program and PCAB pharmacy compounding accreditation), NIOSH HD Group 1 occupational health monitoring records, and state board of pharmacy inspection documentation. In the Surface 1 scenario (22 FPM actual BSC face velocity shown as 95 FPM; +97.4 px adversarial upward shift), Glyphward detects the manipulated BSC airflow display at score 52 and withholds the frame, preventing the compounding approval AI from classifying a containment-failed BSC as USP 800-compliant and stopping mechlorethamine compounding in a BSC with insufficient face velocity before pharmacy technician vesicant exposure begins. In the Surface 2 scenario (0.045 µg/cm² actual surface wipe shown as 0.003 µg/cm²; LC-MS/MS peak area suppression), Glyphward detects the falsified surface wipe report at score 47 and withholds the frame, preventing the environmental monitoring AI from approving a contaminated compounding surface for continued use and triggering the immediate decontamination protocol required by USP 800 Section 8. In the Surface 3 scenario (20% CSTD pressure drop actual shown as 2%; −72 px adversarial downward shift), Glyphward detects the falsified CSTD integrity test at score 43 and withholds the frame, quarantining the defective PhaSeal/Equashield CSTD lot before it is used in mechlorethamine reconstitution, preventing the aerosol generation at the technician’s face that would occur at each vial-septum penetration with a membrane-compromised device. Combined three-surface prevention addresses the complete adversarial containment failure cascade: BSC airflow failure (Surface 1) → mechlorethamine aerosol escapes primary containment → deposits on BSC surfaces (Surface 2 contamination) → CSTD primary containment also compromised (Surface 3) → combined pathway delivers IARC Group 1 vesicant carcinogen to pharmacy technician breathing zone, skin, and mucous membranes with 2–6 hr delayed blistering and lifetime carcinogenic risk accumulation.